$STIM
Neuronetics, Inc.

2019 Form 10-K Financial Statement

#000156459020008464 Filed on March 03, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2018 Q3
Revenue $62.66M $15.64M $13.74M
YoY Change 18.72% 29.13% 30.94%
Cost Of Revenue $15.39M $3.711M $3.034M
YoY Change 23.64% 25.5% 15.1%
Gross Profit $47.27M $11.92M $10.70M
YoY Change 17.2% 30.3% 36.26%
Gross Profit Margin 75.44% 76.26% 77.91%
Selling, General & Admin $60.45M $15.36M $12.91M
YoY Change 16.41% 34.0% 46.34%
% of Gross Profit 127.89% 128.84% 120.62%
Research & Development $13.75M $2.222M $2.125M
YoY Change 67.04% 15.79% 15.3%
% of Gross Profit 29.08% 18.63% 19.85%
Depreciation & Amortization $1.065M $210.0K $210.0K
YoY Change 20.75% 50.0% 40.0%
% of Gross Profit 2.25% 1.76% 1.96%
Operating Expenses $74.20M $17.59M $15.04M
YoY Change 23.33% 31.39% 40.98%
Operating Profit -$26.93M -$5.661M -$4.332M
YoY Change 35.78% 33.73% 54.16%
Interest Expense $3.685M $939.0K $928.0K
YoY Change -0.08% 26.89% 14.99%
% of Operating Profit
Other Income/Expense, Net $1.571M $457.0K $299.0K
YoY Change -373.22% 832.65% -319.85%
Pretax Income -$29.00M -$6.140M -$4.960M
YoY Change 20.33% 24.8% 32.27%
Income Tax
% Of Pretax Income
Net Earnings -$29.00M -$6.143M -$4.961M
YoY Change 20.33% 24.76% 32.19%
Net Earnings / Revenue -46.28% -39.29% -36.11%
Basic Earnings Per Share -$1.58
Diluted Earnings Per Share -$1.58 -$347.7K -$282.1K
COMMON SHARES
Basic Shares Outstanding 18.38M 17.58M
Diluted Shares Outstanding 18.38M

Balance Sheet

Concept 2019 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.70M $104.6M $106.8M
YoY Change -27.63%
Cash & Equivalents $75.70M $104.6M $106.8M
Short-Term Investments
Other Short-Term Assets $2.500M $1.800M $2.100M
YoY Change 38.89%
Inventory $2.800M $2.432M $2.600M
Prepaid Expenses
Receivables $6.600M $5.620M $5.300M
Other Receivables $800.0K $0.00 $0.00
Total Short-Term Assets $88.50M $114.5M $116.7M
YoY Change -22.71% 209.34%
LONG-TERM ASSETS
Property, Plant & Equipment $4.900M $1.378M $1.343M
YoY Change 250.0% 1.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.100M $1.171M $897.0K
YoY Change 325.0% 104.01%
Total Long-Term Assets $11.70M $2.549M $2.240M
YoY Change 368.0% 31.87%
TOTAL ASSETS
Total Short-Term Assets $88.50M $114.5M $116.7M
Total Long-Term Assets $11.70M $2.549M $2.240M
Total Assets $100.2M $117.0M $119.0M
YoY Change -14.36% 200.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.600M $3.756M $2.102M
YoY Change 21.05% 49.46%
Accrued Expenses $9.000M $7.548M $6.383M
YoY Change 26.76% 0.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $11.30M $5.000M
YoY Change
Total Short-Term Liabilities $27.70M $13.56M $15.30M
YoY Change 103.68% 13.05%
LONG-TERM LIABILITIES
Long-Term Debt $19.90M $30.40M $25.20M
YoY Change -34.54% 2.84%
Other Long-Term Liabilities $4.700M $2.000M $2.100M
YoY Change 135.0%
Total Long-Term Liabilities $24.60M $30.40M $25.20M
YoY Change -24.07% 2.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.70M $13.56M $15.30M
Total Long-Term Liabilities $24.60M $30.40M $25.20M
Total Liabilities $52.30M $45.98M $42.63M
YoY Change 13.7% 3.43%
SHAREHOLDERS EQUITY
Retained Earnings -$221.0M
YoY Change 12.24%
Common Stock $292.1M
YoY Change 6702.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.90M $71.04M $76.35M
YoY Change
Total Liabilities & Shareholders Equity $100.2M $117.0M $119.0M
YoY Change -14.36% 200.53%

Cashflow Statement

Concept 2019 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$29.00M -$6.143M -$4.961M
YoY Change 20.33% 24.76% 32.19%
Depreciation, Depletion And Amortization $1.065M $210.0K $210.0K
YoY Change 20.75% 50.0% 40.0%
Cash From Operating Activities -$30.50M -$2.270M -$4.920M
YoY Change 48.06% -940.74% 154.92%
INVESTING ACTIVITIES
Capital Expenditures -$810.0K -$360.0K -$140.0K
YoY Change -19.8% 33.33% -17.65%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$813.0K -$360.0K -$140.0K
YoY Change -19.58% 33.33% -17.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.420M 460.0K 97.27M
YoY Change -97.51% -90.82% 972600.0%
NET CHANGE
Cash From Operating Activities -30.50M -2.270M -4.920M
Cash From Investing Activities -813.0K -360.0K -140.0K
Cash From Financing Activities 2.420M 460.0K 97.27M
Net Change In Cash -28.89M -2.170M 92.21M
YoY Change -138.31% -143.31% -4511.96%
FREE CASH FLOW
Cash From Operating Activities -$30.50M -$2.270M -$4.920M
Capital Expenditures -$810.0K -$360.0K -$140.0K
Free Cash Flow -$29.69M -$1.910M -$4.780M
YoY Change 51.56% -453.7% 171.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-1051425
CY2019 dei Entity File Number
EntityFileNumber
001-38546
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2018Q4 us-gaap Inventory Net
InventoryNet
2432000
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5620000
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
3222 Phoenixville Pike
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
CY2019 dei City Area Code
CityAreaCode
610
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104583000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q4 us-gaap Assets Current
AssetsCurrent
88451000
CY2019Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
1730000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1830000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1107000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3796000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9632000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
38264000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15389000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12447000
CY2017 us-gaap Gross Profit
GrossProfit
30801000
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27900000
CY2018 us-gaap Gross Profit
GrossProfit
40329000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8572000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.480
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.553
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.653
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 stim Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Grant Date Fair Value Of Underlying Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageGrantDateFairValueOfUnderlyingCommonStock
2.90
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
14.27
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.022
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.69
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.03
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10800000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3300000
CY2019 stim Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Grant Date Fair Value Of Underlying Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageGrantDateFairValueOfUnderlyingCommonStock
14.27
CY2018 stim Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Grant Date Fair Value Of Underlying Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageGrantDateFairValueOfUnderlyingCommonStock
8.41
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.41
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2019 dei Local Phone Number
LocalPhoneNumber
640-4202
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75708000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6569000
CY2019Q4 us-gaap Inventory Net
InventoryNet
2775000
CY2019Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
880000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
689000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1838000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
114473000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1378000
CY2019Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
3779000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1305000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1171000
CY2019Q4 us-gaap Assets
Assets
100168000
CY2018Q4 us-gaap Assets
Assets
117022000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4625000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3756000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9031000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7548000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2228000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2255000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
559000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11250000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27693000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13559000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19898000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30395000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2106000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1940000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2619000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
86000
CY2019Q4 us-gaap Liabilities
Liabilities
52316000
CY2018Q4 us-gaap Liabilities
Liabilities
45980000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
186000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
177000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
297753000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
291908000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250087000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221043000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
47852000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
71042000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100168000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117022000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.58
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8948000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18645000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17744000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18645000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17744000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62656000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52776000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40433000
CY2019 us-gaap Gross Profit
GrossProfit
47267000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-26930000
CY2019 us-gaap Interest Expense
InterestExpense
3685000
CY2018 us-gaap Interest Expense
InterestExpense
3688000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1571000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-575000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
357000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-29044000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-24097000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-16059000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.69
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-86.34
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
186000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-177124000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
496000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-192652000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
187136000
CY2018 stim Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrants
AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrants
1874000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96535000
CY2017 stim Stock Issuance Costs On Issuance Of Series G Convertible Preferred Stock
StockIssuanceCostsOnIssuanceOfSeriesGConvertiblePreferredStock
175000
CY2018 stim Issuance Costs On Issuance Of Common Stock
IssuanceCostsOnIssuanceOfCommonStock
3463000
CY2019 us-gaap Profit Loss
ProfitLoss
-29044000
CY2018 us-gaap Profit Loss
ProfitLoss
-24097000
CY2017 us-gaap Profit Loss
ProfitLoss
-16059000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1065000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
882000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
596000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3434000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1743000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
496000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
753000
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
839000
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
722000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1396000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-271000
CY2019 stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
223000
CY2018 stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
229000
CY2017 stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
216000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
950000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1353000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
690000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
306000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
435000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1068000
CY2019 stim Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
2610000
CY2019 stim Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
4468000
CY2019 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
565000
CY2018 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
237000
CY2017 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
175000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
299000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
606000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1549000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2915000
CY2018 us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
63000
CY2017 us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
5000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30482000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20591000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11144000
CY2019 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
813000
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1011000
CY2017 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
594000
CY2018 stim Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
365000
CY2017 stim Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
296000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
377000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
263000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
45000
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
187136000
CY2018 stim Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrant
ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrant
1874000
CY2017 stim Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
55000
CY2017 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
290000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-813000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1011000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-594000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
99998000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3463000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2420000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
503000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35000
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
14825000
CY2017 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
10000000
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1015000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2420000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
97038000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23845000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-28875000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
75436000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104583000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2949000
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.4%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>DESCRIPTION OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuronetics, Inc., or the Company, is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The Company&#8217;s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States Food and Drug Administration, or the FDA, to treat adult patients with major depressive disorder, or MDD, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications.&nbsp;&nbsp;</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2018, the Company closed its initial public offering, or IPO, in which the Company issued and sold 6.325 million shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $17.00 per share. The Company received net proceeds of $96.5 million after deducting underwriting discounts, commissions and other offering expenses paid by the Company. The Company&#8217;s common stock is listed on the Nasdaq Global Market under the trading symbol &#8220;STIM.&#8221; In addition, immediately prior to the closing of the IPO on July 2, 2018, (i) all of the Company&#8217;s outstanding shares of convertible preferred stock converted into an aggregate 11.0 million shares of common stock; (ii) all of the Company&#8217;s outstanding warrants to purchase convertible preferred stock converted into warrants to purchase common stock; and (iii) the Company filed an amended and restated certificate of incorporation to, among other things, decrease the number of shares of common stock, $0.01 par value per share, authorized for issuance to 200.0 million and to authorize the board of directors to issue up to 10.0 million shares of &#8220;blank check&#8221; preferred stock, $0.01 par value per share.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had cash and cash equivalents of $75.7 million and an accumulated deficit of $250.1 million. The Company incurred negative cash flows from operating activities of $30.5 million, $20.6 million and $11.1 million for the years ended December&#160;31, 2019, 2018, and 2017, respectively. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company seeks to expand its sales and marketing initiatives to support its growth into existing and new markets and invest in additional research and development activities. The Company&#8217;s primary sources of capital to date have been from its IPO, private placements of its convertible preferred securities, borrowings under its credit facilities and revenues from sales of its products. As of December&#160;31, 2019, the Company had $30.0 million of borrowings outstanding under its credit facility, which matures in March 2022. Management believes that the Company&#8217;s cash and cash equivalents as of December&#160;31, 2019 and anticipated revenues from sales of its products are sufficient to fund the Company&#8217;s operations for at least the next 24 months after December&#160;31, 2019. </p>
CY2019 us-gaap Basis Of Accounting
BasisOfAccounting
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.4%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>BASIS OF PRESENTATION </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, promulgated by the Financial Accounting Standards Board, or FASB. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the United States Securities and Exchange Commission, or SEC, requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. </p>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the United States Securities and Exchange Commission, or SEC, requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. </p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Management has reviewed the financial statements of this institution and believes it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to the Company. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk principally consist of cash equivalents and accounts receivable. The Company limits its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but it does not require collateral to secure amounts owed by its customers. </p>
CY2018Q3 stim Initial Public Offering Closing Date
InitialPublicOfferingClosingDate
2018-07-02
CY2019Q4 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Revenue Performance Obligation Description Of Warranty
RevenuePerformanceObligationDescriptionOfWarranty
The Company provides a two-year warranty on all new System sales which were determined to be assurance-type warranties and thus not considered a separate performance obligation. The Company accrues the cost of providing these warranties
CY2019Q4 us-gaap Contract With Customer Right To Recover Product
ContractWithCustomerRightToRecoverProduct
0
CY2019 stim Distribution Agreement Period
DistributionAgreementPeriod
P7Y6M
CY2019 stim Distribution Agreement Renewal Period
DistributionAgreementRenewalPeriod
P2Y
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.50
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.12
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.12
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.11
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.11
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.04
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1.00
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2200000
CY2019 stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
0
CY2018 stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
0
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
64182000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53774000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
478000
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1396000
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
1874000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7117000
CY2018Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
6120000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
548000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
500000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
353000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
153000
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
116000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
343000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
417000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
42000
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
70000
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
305000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3314000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3394000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2207000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2016000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2019 us-gaap Lessee Finance Lease Lease Not Yet Commenced Description
LesseeFinanceLeaseLeaseNotYetCommencedDescription
The Company does not currently have any finance leases or executed leases that have not yet commenced.
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2017 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
465000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4164000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
586000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
615000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
639000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
636000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
646000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
2147000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5269000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2091000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3178000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
547000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
560000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
88000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1195000
CY2019 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
1179000
CY2019 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
1179000
CY2019Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
1129000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3434000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1743000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
496000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.45
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.020
CY2019Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
854000
CY2019Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
624000
CY2019Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears
3000
CY2019Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
2610000
CY2019Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
2600000
CY2019Q4 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
0
CY2019 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
700000
CY2018 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
900000
CY2017 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1100000
CY2019Q4 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
470000
CY2019Q4 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
150000
CY2019Q4 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
620000
CY2019 stim Amortization Period Of Deferred Sales Commissions
AmortizationPeriodOfDeferredSalesCommissions
P7Y
CY2019 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
400000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5724000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4909000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
373000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
342000
CY2019Q4 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
674000
CY2018Q4 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
191000
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
127000
CY2018Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
127000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
639000
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
629000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
700000
CY2018Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
606000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
234000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
251000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
560000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
493000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2019Q4 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1838000
CY2018Q4 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1468000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
690000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1073000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
31148000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
30395000
CY2019 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
3700000
CY2018 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
3700000
CY2017 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
2800000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
2900000
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
2900000
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
2100000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
800000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
800000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
700000
CY2017Q1 stim Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
1000000
CY2019Q4 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
23046000
CY2018Q4 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
22159000
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.90
CY2019 us-gaap Defined Contribution Plan Plan Name
DefinedContributionPlanPlanName
401(k) plan
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29000000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24100000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1104000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
523000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
822000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
853000
CY2019Q4 stim Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
1191000
CY2018Q4 stim Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
592000
CY2019Q4 stim Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
1018000
CY2018Q4 stim Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
1295000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
882000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
951000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
62805000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53774000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1377000
CY2019Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Software
DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
283000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16100000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.038
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.064
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.007
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.007
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.006
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.013
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.006
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.380
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.311
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.267
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.003
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56157000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
46352000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3008000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3208000
CY2019Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
1094000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1377000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9000000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6400000
CY2018Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
53774000
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
47341000
CY2019 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
9031000
CY2018 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
6433000
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
62805000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
227000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
142000
CY2019Q4 stim Deferred Tax Assets Operating Loss Carryforwards Research And Development Credits
DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopmentCredits
3000
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019Q2 stim Reimbursement Revenue Per Treatment
ReimbursementRevenuePerTreatment
12000
CY2017 stim Distribution Agreement Renewal Period
DistributionAgreementRenewalPeriod
P2Y
CY2019 stim Distribution Agreements With Renewal Description
DistributionAgreementsWithRenewalDescription
The term of the distribution agreement will be automatically extended for two years unless either party gives the other party at least two years’ prior written of notice of non-renewal, except that the Company cannot decline to renew the agreement if Teijin has purchased 100% of its sales forecasts over the term of the agreement.
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q2 us-gaap Revenues
Revenues
16572000
CY2019Q3 us-gaap Revenues
Revenues
16000000
CY2019Q4 us-gaap Revenues
Revenues
17356000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
4171000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
4192000
CY2019Q4 us-gaap Cost Of Revenue
CostOfRevenue
4219000
CY2019Q2 us-gaap Gross Profit
GrossProfit
12401000
CY2019Q3 us-gaap Gross Profit
GrossProfit
11808000
CY2019Q4 us-gaap Gross Profit
GrossProfit
13137000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11523000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10362000
CY2019Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11516000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4261000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4285000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4312000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3224000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3489000
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4248000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
19008000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
18136000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
20076000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6607000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6328000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6939000
CY2019Q2 us-gaap Interest Expense
InterestExpense
931000
CY2019Q3 us-gaap Interest Expense
InterestExpense
930000
CY2019Q4 us-gaap Interest Expense
InterestExpense
905000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
444000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
391000
CY2019Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
290000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7094000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6867000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-7554000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18351000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18508000
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18627000
CY2018Q1 us-gaap Revenues
Revenues
10152000
CY2018Q2 us-gaap Revenues
Revenues
13252000
CY2018Q3 us-gaap Revenues
Revenues
13737000
CY2018Q4 us-gaap Revenues
Revenues
15635000
CY2018Q1 us-gaap Cost Of Revenue
CostOfRevenue
2457000
CY2018Q2 us-gaap Cost Of Revenue
CostOfRevenue
3245000
CY2018Q3 us-gaap Cost Of Revenue
CostOfRevenue
3034000
CY2018Q4 us-gaap Cost Of Revenue
CostOfRevenue
3711000
CY2018Q1 us-gaap Gross Profit
GrossProfit
7695000
CY2018Q2 us-gaap Gross Profit
GrossProfit
10007000
CY2018Q3 us-gaap Gross Profit
GrossProfit
10703000
CY2018Q4 us-gaap Gross Profit
GrossProfit
11924000
CY2018Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8109000
CY2018Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9835000
CY2018Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9672000
CY2018Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10648000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2636000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3078000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3238000
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4715000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1555000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2330000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2125000
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2222000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
12300000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15243000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
15035000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
17585000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4605000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5236000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4332000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5661000
CY2018Q1 us-gaap Interest Expense
InterestExpense
921000
CY2018Q2 us-gaap Interest Expense
InterestExpense
900000
CY2018Q3 us-gaap Interest Expense
InterestExpense
928000
CY2018Q4 us-gaap Interest Expense
InterestExpense
939000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1360000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
299000
CY2018Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
457000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5497000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-7496000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-4961000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-6143000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-24.43
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-30.60
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
226000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
245000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17382000
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17655000
CY2018Q3 us-gaap Sale Of Stock Transaction Date
SaleOfStockTransactionDate
2018-07-02

Files In Submission

Name View Source Status
0001564590-20-008464-index-headers.html Edgar Link pending
0001564590-20-008464-index.html Edgar Link pending
0001564590-20-008464.txt Edgar Link pending
0001564590-20-008464-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stim-10k_20191231.htm Edgar Link pending
stim-20191231.xml Edgar Link completed
stim-20191231.xsd Edgar Link pending
stim-20191231_cal.xml Edgar Link unprocessable
stim-20191231_def.xml Edgar Link unprocessable
stim-20191231_lab.xml Edgar Link unprocessable
stim-20191231_pre.xml Edgar Link unprocessable
stim-ex231_7.htm Edgar Link pending
stim-ex311_8.htm Edgar Link pending
stim-ex312_9.htm Edgar Link pending
stim-ex321_6.htm Edgar Link pending
stim-ex44_309.htm Edgar Link pending